Ironside JW - Search Results

1

Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders.

Di Minno G, Perno CF, Tiede A, Navarro D, Canaro M, Güertler L, Ironside JW. Di Minno G, et al. Among authors: ironside jw. Blood Rev. 2016 Jan;30(1):35-48. doi: 10.1016/j.blre.2015.07.004. Epub 2015 Jul 20. Blood Rev. 2016. PMID: 26381318 Free PMC article. Review.

2

Pathogen safety of long-term treatments for bleeding disorders: (un)predictable risks and evolving threats.

Di Minno G, Canaro M, Ironside JW, Navarro D, Perno CF, Tiede A, Guertler L. Di Minno G, et al. Among authors: ironside jw. Semin Thromb Hemost. 2013 Oct;39(7):779-93. doi: 10.1055/s-0033-1354420. Epub 2013 Sep 12. Semin Thromb Hemost. 2013. PMID: 24030344 Review.

3

Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice.

Di Minno G, Canaro M, Ironside JW, Navarro D, Perno CF, Tiede A, Gürtler L. Di Minno G, et al. Among authors: ironside jw. Haematologica. 2013 Oct;98(10):1495-8. doi: 10.3324/haematol.2013.084145. Haematologica. 2013. PMID: 24091928 Free PMC article. No abstract available.

4

Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?

Di Minno G, Navarro D, Perno CF, Canaro M, Gürtler L, Ironside JW, Eichler H, Tiede A. Di Minno G, et al. Among authors: ironside jw. Ann Hematol. 2017 Aug;96(8):1253-1270. doi: 10.1007/s00277-017-3028-4. Epub 2017 Jun 18. Ann Hematol. 2017. PMID: 28624906 Free PMC article. Review.

5

Convalescent plasma for administration of passive antibodies against viral agents.

Di Minno G, Mannucci PM, Ironside JW, Perno CF, Gürtler L, Aledort L. Di Minno G, et al. Among authors: ironside jw. Haematologica. 2020 Dec 1;105(12):2710-2715. doi: 10.3324/haematol.2020.267427. Haematologica. 2020. PMID: 33256373 Free PMC article. No abstract available.

6

New-variant Creutzfeldt-Jakob disease: the risk of transmission by blood transfusion.

Turner ML, Ironside JW. Turner ML, et al. Among authors: ironside jw. Blood Rev. 1998 Dec;12(4):255-68. doi: 10.1016/s0268-960x(98)90007-8. Blood Rev. 1998. PMID: 9950096 Review.

7

Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products.

Ironside JW, Head MW. Ironside JW, et al. Haemophilia. 2004 Oct;10 Suppl 4:64-9. doi: 10.1111/j.1365-2516.2004.00982.x. Haemophilia. 2004. PMID: 15479374 Review.

8

Variant Creutzfeldt-Jakob disease: risk of transmission by blood transfusion and blood therapies.

Ironside JW. Ironside JW. Haemophilia. 2006 Mar;12 Suppl 1:8-15; discussion 26-8. doi: 10.1111/j.1365-2516.2006.01195.x. Haemophilia. 2006. PMID: 16445812 Review.

9

Variant Creutzfeldt-Jakob disease and its transmission by blood.

Ironside JW, Head MW. Ironside JW, et al. J Thromb Haemost. 2003 Jul;1(7):1479-86. doi: 10.1046/j.1538-7836.2003.00268.x. J Thromb Haemost. 2003. PMID: 12871283 Free article. Review.

10

Risk reduction strategies for variant Creutzfeldt-Jakob disease transmission by UK plasma products and their impact on patients with inherited bleeding disorders.

Millar CM, Connor N, Dolan G, Lee CA, Makris M, Wilde J, Winter M, Ironside JW, Gill N, Hill FG. Millar CM, et al. Among authors: ironside jw. Haemophilia. 2010 Mar;16(2):305-15. doi: 10.1111/j.1365-2516.2010.02220.x. Haemophilia. 2010. PMID: 20487442

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

428 results

Search Page

Filters